Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.

Tyrosine kinase inhibitor (TKI) therapy has revolutionised chronic myeloid leukaemia (CML) management, it is however associated with significant side effects and economic burden. Recent studies have demonstrated that treatment free remission is possible in certain patients. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: McMullan, RR, McConville, C, McMullin, MF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Ulster Medical Society 2019
Materias:
Clinical Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500416/
https://www.ncbi.nlm.nih.gov/pubmed/31061559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500416/
https://www.ncbi.nlm.nih.gov/pubmed/31061559

Ejemplares similares